Neurone specific enolase immunostaining in the diagnosis of breast carcinomas with neuroendocrine differentiation. Its usefulness and limitations

Nesland, Jahn M.; Holm, Ruth; Johannessen, Jan Vincents; Gould, Victor E.

doi:10.1002/path.1711480107

Cited by 67 publications

(24 citation statements)

References 15 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3c show that it is also expressed in non-endocrine lung tumor cells except adenocarcinomas. Similarly, NSE has been detected in non-SCLC [25,31,32J and also in other human tissues and neoplasms with non-endocrine characteristics [33][34][35]. The immunoblots shown here (Fig.…”

Section: Resultssupporting

confidence: 60%

NCAM: A surface marker for human small cell lung cancer cells

1991

Lung Cancer

View full text Add to dashboard Cite

Immunocytochemical and immunochemical techniques were used to study the expression of the neural cell adhesion molecule (NCAM) by human lung cancer cell lines. Intense surface staining for NCAM was found at light and electron microscopic levels on small celliung cancer cells. The NCAM polypeptide of M r 140000 (NCAM 140) was detected by immunoblotting in all of 7 small celliung cancer celllines examined and in one out of two of the closely related large cell cancer cell lines: it was not detected in cell lines obtained from one patient with a mesothelioma, in two cases of adenocarcinoma, nor in two cases of squamous cell cancer. In contrast, neuron-specific enolase was found by immunoblotting in all the lung cancer celliines tested and synaptophysin in all but the adenocarcinoma celliines. These antigens were localized intracellularly. The specific expression ofNCAM 140 by human small and large celliung carcinomas suggests its potential as a diagnostic marker.Lung cancer; Neural cell adhesion molecule; Marker

show abstract

Section: Resultssupporting

confidence: 60%

NCAM: A surface marker for human small cell lung cancer cells

1991

Lung Cancer

View full text Add to dashboard Cite

show abstract

“…Comparing this theoretical possibility to our findings and those from others [10][11][12][13][14][15][16][17]34], we can state with confidence that in malignant cells the presence of y-enolase does not prove a neuronal or neuroendocrine cell of origin. Nevertheless, in tumors de rived from those cells, y-enolase may be present in high quantities, stressing the im portance of quantitative analysis in addition to immunohistochemistry.…”

Section: Discussionsupporting

confidence: 53%

Enolase Isoenzymes in Human Cerebral Metastasis

Doel¹,

Roholl²,

Rijksen³

et al. 1989

Tumor Biol

View full text Add to dashboard Cite

γ-Enolase [one of the three possible subunits of the dimeric enzyme enolase (EC 4.2.1.11)] has been reported as a marker for human neurons, neuroendocrine cells and tumors derived from these cells. In recent years, however, its presence has been reported in nonneuronal tumors. For employment in the histopathologic diagnosis of tumors of the nervous system, exact knowledge of the enolase isoenzyme patterns occurring in these tumors is a prerequisite. In human gliomas, the presence of varying quantities of γ-enolase has been demonstrated. The present study examines the enolase isoenzyme pattern in human cerebral metastases of various primary progeny, using electrophoresis of tumor tissue extracts as well as immunohistochemistry. Additionally, a number of primary tumors of nonneuroepithelial tissue was examined by immunohistochemistry. The presence of γ-enolase was demonstrated in a significant number of brain metastases. A relation between enolase isoenzyme pattern and survival after operation for brain metastasis could not be found. For histopathologic diagnosis of tumors of the adult human central nervous system, analysis of the enolase isoenzyme pattern is not reliable.

show abstract

“…Chromogranin and synaptophysin show the best sensitivity and specificity as immunohistochemical neuroendocrine markers [10]. Also neuron-specific enolase can be occasionally positive in NECB [11], whereas CD56 and other immunohistochemical markers seem to be less sensitive and specific [12].…”

Section: Pathological Classificationmentioning

confidence: 97%

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

et al. 2015

View full text Add to dashboard Cite

Neuroendocrine carcinoma of the breast is considered a rare entity, and for this reason there are no data from prospective clinical trials on its optimal management. Early stage tumors are usually treated with the same strategy used for the other types of invasive breast cancer. Anthracycline-and taxane-based regimens represent the most frequently administered chemotherapy in neoadjuvant and adjuvant setting, as well as for metastatic disease, although combinations of platinum compounds and etoposide have been widely used, in particular for small-cell histology and tumors with a high proliferation index. For metastatic disease, a multimodality therapeutic strategy can be considered on an individual basis, with chemotherapy, endocrine therapy, peptide receptor radionuclide therapy, radiation therapy, surgery, or a combination of the above. In the near future, a better knowledge of the biology of these tumors will hopefully provide new therapeutic targets for personalized treatment. In this review, we discuss the current evidence and the future perspectives on diagnosis and treatment of neuroendocrine carcinoma of the breast. The Oncologist 2016;21:28-32 Implications for Practice: Neuroendocrine carcinoma of the breast (NECB) is a distinct entity of breast cancer. Clinical features and morphology are not helpful to distinguish NECB from other subtypes of breast cancer; therefore, immunohistochemistry markers for neuroendocrine differentiation, mainly chromogranin and synaptophysin, should be routinely used to confirm the diagnosis, especially in cases of mucinous or solid papillary carcinoma in which the suspicion of NECB may be relevant. Adjuvant treatment should be offered according to the same recommendations given for the other types of invasive breast cancer. An accurate diagnosis of NECB is also important in the metastatic setting, in which a multimodality approach including specific therapies such as peptide receptor radionuclide therapy can be considered.

show abstract

Neurone specific enolase immunostaining in the diagnosis of breast carcinomas with neuroendocrine differentiation. Its usefulness and limitations

Cited by 67 publications

References 15 publications

NCAM: A surface marker for human small cell lung cancer cells

NCAM: A surface marker for human small cell lung cancer cells

Enolase Isoenzymes in Human Cerebral Metastasis

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

Contact Info

Product

Resources

About